Substance Abuse and Rehabilitation

Substance Abuse and Rehabilitation is an open access journal launched in 2010 by Dove Medical Press in Auckland, New Zealand.《物质滥用与康复》是 2010 年由新西兰奥克兰的 Dove Medical Press 创办的开放获取期刊。

It publishes work on addiction and substance misuse, together with the treatment and rehabilitation options that follow from it.刊物发表成瘾与物质滥用方面的研究，以及由此展开的治疗与康复方案。

Its 2025 Journal Impact Factor is 3.2, with a five-year value of 5.7, and it ranks 15th among 61 titles in substance abuse.2025 年期刊影响因子为 3.2，五年影响因子为 5.7，在物质滥用领域 61 种期刊中排第 15 位。

Scope

• Alcohol use and alcohol use disorder form a large share of the content, from screening and brief intervention to relapse prevention.酒精使用与酒精使用障碍占内容的很大比重，从筛查与简短干预到预防复饮。
• Opioid dependence is covered through agonist therapy, overdose prevention and the organisation of treatment services.阿片依赖通过激动剂治疗、过量预防与治疗服务的组织得到讨论。
• Stimulant, cannabis and nicotine dependence appear with pharmacological and behavioural approaches side by side.兴奋剂、大麻与尼古丁依赖在药物与行为途径并列的框架下出现。
• Polysubstance use and the interaction between substances are treated as clinical problems rather than as a footnote.多药合用以及物质之间的相互作用被当作临床问题处理，而不是附注。
• Pharmacotherapy papers examine methadone, buprenorphine, naltrexone and newer agents, with dosing and adherence as recurring questions.药物治疗论文考察美沙酮、丁丙诺啡、纳曲酮与较新的药物，剂量与依从性是反复出现的问题。
• Psychosocial treatments are reported with their theoretical basis, including motivational interviewing, contingency management and cognitive behavioural work.心理社会治疗连同理论依据一并报告，包括动机式访谈、行为强化与认知行为工作。
• Harm reduction is within the remit, and needle exchange, supervised consumption and naloxone distribution have all appeared in its pages.减害属于收稿范围，针具交换、监督使用与纳洛酮发放都曾在刊物中出现。
• Recovery and reintegration are studied through housing, employment and peer support programmes.康复与重新融入通过住房、就业与同伴支持项目得到研究。
• Dual diagnosis papers address the overlap between substance use and psychiatric illness, including anxiety, depression and trauma.双重诊断论文讨论物质使用与精神疾病的重叠，包括焦虑、抑郁与创伤。
• Adolescent and young adult substance use is covered with attention to development, family context and school-based prevention.青少年与青年物质使用研究关注发育、家庭环境与学校预防。
• Criminal justice settings appear through diversion programmes, treatment in custody and continuity of care after release.刑事司法场景通过转处项目、羁押期间治疗与释放后的照护衔接出现。
• Health services research examines access, retention in treatment, stigma and the cost of care for people who use drugs.卫生服务研究考察可及性、治疗留存、污名以及药物使用者的照护成本。
• Epidemiology and surveillance papers describe prevalence, trends and the emergence of new substances.流行病学与监测论文描述患病率、趋势以及新物质的出现。
• Qualitative studies of lived experience and of service delivery are accepted alongside quantitative designs.亲身经历与服务提供方面的质性研究，与定量设计并列接受。
• The journal publishes case reports, study designs and methods, statistical designs and study protocols as well as full research papers.刊物除完整研究论文外，也发表病例报告、研究设计与方法、统计设计以及研究方案。
• Since August 2025 the journal has stated that it no longer considers meta-analyses for publication.自 2025 年 8 月起，刊物声明不再接受荟萃分析类稿件。
• Prescription drug misuse and the transition from medical use to dependence are treated as distinct clinical problems.处方药误用以及从医疗使用转向依赖的过程被当作独立的临床问题。
• Telehealth and digital interventions are reported with attention to retention, privacy and the digital divide.远程医疗与数字干预在报告中关注留存、隐私与数字鸿沟。

• Prescription monitoring programmes and pharmacy-level controls are examined as policy levers for misuse.处方监测项目与药房层面的管控被当作应对误用的政策工具加以考察。
• Opioid agonist treatment in rural and low-resource settings is reported with attention to access and continuity.农村与资源匮乏环境中的阿片激动剂治疗在报告中关注可及性与连续性。

History

• The title was established in 2010 by Dove Medical Press, an open access publisher based in Auckland.该刊于 2010 年由总部位于奥克兰的开放获取出版商 Dove Medical Press 创办。
• It has appeared online only, without a print edition, and articles are gathered into an annual volume.刊物只在网络出版，没有印刷版，文章按年度卷汇集。
• All content is gold open access, and authors pay an article publishing charge rather than readers paying a subscription.全部内容为金色开放获取，由作者支付文章出版费，而不是读者支付订阅费。
• The journal is a member of the Committee on Publication Ethics and follows its guidance on misconduct and corrections.刊物是出版伦理委员会成员，并遵循其关于不端行为与更正的处理准则。
• Dove Medical Press became part of the Taylor and Francis group, and the journal is now published within that structure.Dove Medical Press 已并入泰勒-弗朗西斯集团，该刊目前在这一体系内出版。
• Impact factors were 5.1 in 2023 and 5.9 in 2024 before settling at 3.2 in 2025.影响因子在 2023 年为 5.1，2024 年为 5.9，2025 年为 3.2。
• The 2025 report counted 864 citations, 20 articles and 23 citable items, a small output relative to the citation base.2025 年报告统计被引 864 次，论文 20 篇，可引用条目 23 项，相对其被引规模而言发文量很小。
• The title is indexed in the Emerging Sources Citation Index, Scopus and the Directory of Open Access Journals.该刊被新兴来源引文索引、Scopus 与开放获取期刊目录收录。
• Editorial decisions are handled through the publisher's online system, and the journal publishes its peer review policy on the site.编辑决定通过出版方的在线系统处理，刊物在网站上公布同行评审政策。
• The journal issues calls for papers on specific topics, which are listed alongside its general scope statement.刊物就特定主题发布征稿通知，与总体范围说明并列公布。
• Its readership includes clinicians in addiction services, public health staff and researchers in health services and policy.读者包括成瘾服务机构的临床医生、公共卫生人员以及卫生服务与政策研究者。
• Volumes are numbered annually, and the journal has published continuously since its first volume in 2010.刊物按年编卷，自 2010 年第一卷起连续出版。

Editors

• Rajendra D. Badgaiyan is editor-in-chief and chief of psychiatry at the South Texas Veterans Health Care System in San Antonio.Rajendra D. Badgaiyan 担任主编，是圣安东尼奥南得克萨斯退伍军人医疗系统的精神科主任。
• He trained in psychiatry at Harvard Medical School and has held posts at Harvard, the University at Buffalo and the University of Minnesota.他在哈佛医学院接受精神科训练，先后任职于哈佛、布法罗大学与明尼苏达大学。
• His research concerns neurotransmitter imaging and the dopaminergic control of cognition and behaviour.他的研究涉及神经递质成像以及多巴胺对认知与行为的调控。
• The editorial board lists fifteen members, most of them based in the United States, with others in Canada, the United Kingdom and France.编委会列出十五名成员，多数在美国，另有加拿大、英国与法国学者。
• Stephan Arndt of the University of Iowa brings biostatistics and programme evaluation to the board.爱荷华大学的 Stephan Arndt 把生物统计与项目评估带入编委会。
• Kenneth Blum works on reward deficiency and addiction genetics, and Caroline Davis of York University studies eating behaviour and addiction.Kenneth Blum 研究奖赏缺陷与成瘾遗传学，约克大学的 Caroline Davis 研究进食行为与成瘾。
• Peter Hajek of Queen Mary University of London directs a tobacco dependence research unit and is a board member.伦敦玛丽女王大学的 Peter Hajek 主持烟草依赖研究单位，是编委之一。
• Walter Ling of the University of California, Los Angeles, has run integrated substance abuse programmes and sits on the board.加州大学洛杉矶分校的 Walter Ling 主持过整合性物质滥用项目，也在编委会中。
• Michael Zvolensky of the University of Houston and Florence Noble of Universite Paris cite extend the board into anxiety research and neuropharmacology.休斯敦大学的 Michael Zvolensky 与巴黎西岱大学的 Florence Noble 把编委会扩展到焦虑研究与神经药理学。
• Manuscripts are screened in house before external review, and reports are sought from reviewers with clinical or policy experience.稿件在送外审前先在编辑部初筛，审稿意见来自具备临床或政策经验的评审人。
• Levent Kirisci of the University of Pittsburgh and Celia Lo of Texas Woman's University add measurement and sociological perspectives.匹兹堡大学的 Levent Kirisci 与得克萨斯女子大学的 Celia Lo 带来测量学与社会学视角。
• Thomas Wickizer of Ohio State and Angela Robertson of Mississippi State work on health services and community-based evaluation.俄亥俄州立大学的 Thomas Wickizer 与密西西比州立大学的 Angela Robertson 研究卫生服务与社区评估。